Proactive Investors - Run By Investors For Investors

FuturaGene unit in collaboration deal with Oregon State University

FuturaGene unit in collaboration deal with Oregon State University

FuturaGene PLC (AIM: FGN)  said its unit CBD Technologies Ltd has entered into a collaborative agreement with Oregon State University under which it will provide professor Steven Strauss’ research group at the Forest Biotechnology department with a proprietary eucalyptus clone and a highly efficient eucalyptus transformation protocol.

The collaboration will facilitate rapid and efficient evaluation of genes for flowering control and other biosafety aspects of tree modification.

In addition CBD Tech plans to join the Tree Biosafety and Genomics Research Cooperative (TBGRC), an internationally recognised tree research consortium that has been working with forest industries on tree biotechnology for 15 years and which is directed by Professor Strauss.

Although eucalyptus is the most widely planted commercial plantation tree species for pulp and paper production in the world, this species is notoriously difficult to transform, FurturaGene said in a statement.

Thus, the supply of a proprietary clone and transformation method from the company to a public research institute, under appropriate material usage and confidentiality provisions, represents a significant contribution to accelerating public research and development in this species, it added.

Register here to be notified of future FGN Company articles
View full FGN profile

Futuragene Timeline

Related Articles

April 26 2016
Dr Stewart White, Collagen Solutions chief executive, told investors that the new partnership will expedite the roll-out of its medical grade collagen to customers in China.
March 02 2016
The company's results reveal a company in rude health - and one still on the acquisition trial.
Knee surgery
October 12 2016
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.